Genmab Expands Blood Cancer Pipeline With First-in-Human GEN3018 Trial

Genmab (Otc) (GMAB) announced an update on their ongoing clinical study.

Genmab (OTC: GMAB) is starting a first-in-human study of GEN3018 in patients with relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndrome. The trial aims to test safety, find the right dose, and look for early signs that the drug can control disease in these hard-to-treat blood cancers.

GEN3018 is an experimental antibody given by intravenous infusion. It is designed to target cancer cells in the blood and bone marrow and could expand Genmab’s presence in acute leukemia and related disorders if it proves safe and active.

The study is an interventional Phase 1 trial where all participants receive GEN3018 and there is no placebo arm. Doses are increased step by step in the first part, and then refined in the second part, with no blinding and a main goal of testing a treatment rather than comparing different options.

The trial plans to treat up to 78 participants over two parts, with around one year of treatment per patient and regular follow-up checks. The study was first submitted on Jan. 27, 2026, and the record was last updated on Feb. 17, 2026, signaling that the design is current and the trial is actively recruiting.

For investors, this update adds a new early-stage asset to Genmab’s pipeline in a high-need cancer segment, which can support long-term growth expectations if early safety and activity look promising. However, as an early Phase 1 oncology trial, near-term earnings impact is limited and risk of failure remains high, so sentiment will likely hinge on initial dose-escalation data and how GEN3018 stacks up against other emerging AML and MDS treatments.

The GEN3018 trial is now ongoing with active recruitment, and further details and updates are available on the ClinicalTrials.gov portal.

To learn more about GMAB’s potential, visit the Genmab (Otc) drug pipeline page.